EMC Capital Management Trims Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

EMC Capital Management decreased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 22.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,074 shares of the company’s stock after selling 2,030 shares during the quarter. EMC Capital Management’s holdings in Prestige Consumer Healthcare were worth $552,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. boosted its position in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after acquiring an additional 433 shares during the last quarter. nVerses Capital LLC raised its stake in Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Huntington National Bank boosted its holdings in shares of Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of Prestige Consumer Healthcare by 7,112.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after buying an additional 1,138 shares during the period. Finally, GAMMA Investing LLC increased its holdings in shares of Prestige Consumer Healthcare by 49.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,163 shares of the company’s stock worth $84,000 after buying an additional 387 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH opened at $79.11 on Thursday. The business’s 50-day simple moving average is $79.97 and its 200 day simple moving average is $75.05. The company has a market cap of $3.91 billion, a P/E ratio of 19.25, a PEG ratio of 2.17 and a beta of 0.51. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. Prestige Consumer Healthcare Inc. has a one year low of $60.00 and a one year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter last year, the firm posted $1.07 earnings per share. On average, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PBH. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Monday, December 9th. DA Davidson reiterated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Finally, StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $85.25.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares in the company, valued at $1,505,930. This trade represents a 33.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 in the last quarter. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.